Name: 글로벌 시장 동향
SKU: PH1784
Availability: InStock

보고서 요약(국문)

개요
전 세계 심낭염 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
심낭염은 심장을 둘러싸는 막인 심낭의 염증으로, 주로 바이러스 감염, 루푸스와 같은 염증성 질환, 류마티스 관절염 등이 원인입니다. 항염증제와 코르티코스테로이드가 심낭염 치료에 사용됩니다. 심낭염은 지속 기간에 따라 급성 심낭염과 만성 심낭염으로 나뉩니다. 또한, 코로나19 환자에게서도 나타나는데, 이는 독감 감염으로 인한 것이기 때문입니다.
미국 국립생명공학정보센터(NCBI)에 따르면, 일반 인구에서 급성 심낭염의 발생률은 연간 인구 10만 명당 약 27.7건입니다. 심낭염 감염은 바이러스, 세균, 곰팡이 등 다양한 원인에 의해 발생하며, 증상은 크게 다르지 않습니다. 거의 모든 사람에게 흉통, 발한, 호흡곤란을 유발합니다.
시장 동향: 동인 및 제약 요인
바이러스 관련 심낭염의 유병률 증가
바이러스 감염은 전 세계적으로 심낭염의 주요 원인이며, 심낭염은 바이러스 감염과 함께 발생하는 경우가 많습니다. 하버드 헬스에 따르면, 심낭염의 초기 유발 요인은 바이러스 감염으로, 심장을 포함한 여러 장기에 체액이 축적됩니다. 질병의 원인이 바이러스, 박테리아, 자가면역 질환 등 여러 요인에 따라 달라지기 때문에 예방보다는 치료가 더 효과적입니다.
세계보건기구(WHO)의 2022년 보고서에 따르면, 매년 계절성 독감과 관련된 호흡기 질환으로 약 65만 명이 사망합니다. 독감은 감염이 심장으로 퍼져 심낭에 염증을 일으켜 심낭염을 유발합니다.
코로나19 또한 독감 바이러스가 신체의 거의 모든 부위로 퍼져 염증을 유발하면서 심낭염 사례를 보고했습니다. 2022년 12월 기준, 6,618,579명의 코로나19 사망자가 보고되었으며, 이들 대부분은 심장 염증을 앓고 있었습니다. 예를 들어, 미국심장협회(AHA) 저널 2023년호에 따르면, SARS-CoV-2는 심근염/심막염 발생률을 코로나19 이전 수준보다 최소 15배 이상 증가시켰지만, 이 질환 자체는 여전히 드문 질환입니다.
또한, 심장 질환의 유병률 증가, 혁신 증가, 그리고 더 나은 진단 및 치료법의 발전은 향후 시장 성장을 견인하는 요인입니다.
심막절제술의 부작용
심막절제술의 부작용으로는 과다 출혈, 심방 및 심실 부정맥, 심지어 심실벽 파열 등이 있습니다. 일부 환자에게서는 혈전 및 감염이 관찰되기도 합니다. 이러한 시술 자체가 위험하기 때문에 위험을 극복하기는 어렵습니다. 따라서 대부분의 심막염 환자는 부작용이 적고 치료가 가능한 항염증제를 사용하여 치료합니다.
세그먼트 분석
전 세계 심낭염 시장은 질병 유형, 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
항염증제 부문은 시장 점유율의 약 45.8%를 차지했습니다.
항염증제는 심낭염의 1차 치료제입니다. 현재 여러 기업에서 효능과 안전성을 향상시킨 항염증제 개발을 진행하고 있습니다. 미국 식품의약국(FDA)은 카디올 테라퓨틱스(Cardiol Therapeutics Inc.)가 희귀 심장 질환인 재발성 심낭염과 급성 심근염에 대한 두 건의 2상 임상 연구를 진행하는 것을 지원하고 있습니다. 현재까지 심낭염과 같은 희귀 심장 질환에 대한 다른 치료제는 발견되지 않았기 때문입니다.
2022년 11월, 카디올 테라퓨틱스는 카디올Rx의 보호 효과를 입증하는 긍정적인 결과를 발표했습니다. 카디올Rx는 심낭 삼출 및 심낭 비후를 유의미하게 감소시키는 것으로 나타났습니다.

2023년 1월, 카디올 테라퓨틱스(Cardiol Therapeutics Inc.)는 재발성 심낭염 환자를 대상으로 카디올Rx의 내약성, 안전성 및 효능을 평가하는 자사 주도 2상 임상 연구에 첫 번째 환자가 등록되었다고 발표했습니다.
지역 분석
북미는 2022년 시장 점유율의 약 40.6%를 차지했습니다.
미국 기업이 개발한 백신 접종 환자에게서 심낭염 발병률이 높기 때문에 북미는 앞으로도 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 심낭염은 전 세계적으로 6,400만 명 이상에게 영향을 미치는 심부전을 유발하며, 미국에서만 관련 의료비용이 연간 300억 달러를 초과합니다. 심낭염은 모든 심혈관 질환 입원 환자의 0.2%에서 진단되며, 북미와 서유럽에서 흉통으로 응급실을 찾는 환자의 5%를 차지합니다.

캐나다에서는 2,200만 도스 이상의 모더나 백신이 접종되었으며, 모더나 스파이크백스(Spikevax) 코로나19 백신 2차 접종 후 심근염, 심낭염 또는 심근심낭염 발생률이 화이자 백신보다 2~3배 높은 것으로 나타났습니다. 캐나다에서는 모더나 백신 접종 직후 41건의 심낭염 사례가 관찰되었습니다.
코로나19 영향 분석
코로나19는 심낭염 시장에 경미하거나 중간 정도의 영향을 미쳤습니다. 감염이 최고조에 달했던 시기에 공급망이 중단되었고, 전 세계적인 봉쇄 조치로 대부분의 진단 센터가 문을 닫았습니다. 이는 심낭염을 포함한 심혈관 질환의 진단 및 치료 절차에 영향을 미쳤습니다.
심낭염은 원인이 다양하고 치료법도 제각각이며, 환자마다 광범위한 검사가 필요하지만 코로나19 기간 동안 이러한 검사가 전면 중단되면서 많은 환자들이 진단이 늦어지고 더 진행된 단계에 이르렀습니다. 따라서 모든 연구는 백신 및 코로나19 치료제 개발에 집중되었습니다.

경쟁 환경
심낭염 시장의 주요 글로벌 업체로는 Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Merck KGaA, Cumberland Pharmaceuticals Inc., Johnson & Johnson Inc., Bayer AG, Midas Pharma GmbH., Alchem International Pvt. Ltd., Takeda Pharmaceutical Company Limited, Azure Pharmaceuticals 등이 있습니다.
주요 개발 사항
• 라빈 메디컬 센터(Rabin Medical Center)는 심낭염 환자를 대상으로 NSAID 요법과 덱사메타손 요법의 효능을 비교하는 4상 임상 시험을 진행하고 있습니다. 이 연구는 2020년 2월 14일에 시작하여 2023년 12월에 완료될 예정입니다.
• 2021년 3월, 키니크사 파마슈티컬스(Kiniksa Pharmaceuticals, Ltd.)는 성인 및 12세 이상 소아의 재발성 심낭염 치료 및 재발 위험 감소를 위한 ARCALYST에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. ARCALYST는 2021년 8월에 상용화되었습니다.
보고서 구매 이유

• 질병 유형, 치료 유형, 최종 사용자 및 지역별 글로벌 심낭염 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 심낭염 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

글로벌 심낭염 시장 보고서는 약 63개의 표, 65개의 그림, 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Pericarditis Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Pericarditis is caused by inflammation of the pericardium, the lining of the heart, mainly driven by viruses, inflammatory diseases like lupus, and rheumatoid arthritis. Anti-inflammatory agents and corticosteroids are used for the treatment of pericarditis. Based on its duration, it is of two types, acute and chronic pericarditis. It is also seen in COVID patients as it is caused by flu infection.
According to the National Center for Biotechnology Information, the incidence of acute pericarditis in the general population is approximately 27.7 cases per 100,000 individuals annually. However, pericarditis infection has many causes, such as viral, bacterial, fungal, etc. The symptoms don't vary much. It causes chest pain, sweating, and breathlessness in almost every individual.
Market Dynamics: Drivers & Restraints
Increasing prevalence of virus-associated pericarditis
Viral infections are a leading cause of pericarditis worldwide, as the condition frequently coexists with viral infections. According to Harvard Health, the initial trigger for pericarditis is viral infections, as they cause fluid accumulation in various organs, including the heart. Treatment is more feasible than prevention because the cause of the disease is dependent on many factors, such as viruses, bacteria, autoimmune disorders, etc.
According to the World Health Organisation 2022 issue, every year, an estimated 650,000 deaths are caused due to respiratory diseases linked to seasonal influenza alone. Influenza leads to pericarditis as the infection moves to the heart and causes inflammation in the pericardium.
COVID-19 also reported pericarditis cases as the flu spread to almost every part of the body and caused inflammation. As of December 2022, 6,618,579 COVID deaths have been reported, most of which had heart inflammation. For instance, according to the AHA journal 2023 issue, SARS-CoV-2 increased the incidence of myocarditis/pericarditis by at least 15× over pre-COVID levels, although the condition remains rare.
Furthermore, increased prevalence of heart diseases, increased innovations, and advancements in better diagnosis and treatment are the factors that drive the market in the forthcoming period.
Side effects of pericardiectomy
Side effects of Pericardiectomy include excessive bleeding, atrial and ventricular arrhythmia, and even ventricular wall rupture. Blood clots and infection are also observed in a few patients undergoing Pericardiectomy. Overcoming these risks is difficult as the procedures are risky to perform. Hence, most pericarditis cases are treated using anti-inflammatory drugs, which causes fewer side effects that are often treatable.
Segment Analysis
The global pericarditis market is segmented based on disease type, treatment type, end user and region.
The Anti inflammatory drugs segment accounted for approximately 45.8% of the market share
Anti-inflammatory drugs are the first-line treatment for pericarditis. Companies are currently working on the same with increased efficacy and safety. The United States Food and Drug Administration is supporting Cardiol Therapeutics Inc. in conducting two Phase II studies in rare heart diseases, recurrent pericarditis, and acute myocarditis, as no other drugs are currently discovered for rare heart diseases like pericarditis.
In November 2022, Cardiol Therapeutics Inc. declared positive results demonstrating the protective effects of CardiolRx. It significantly reduces pericardial effusion and thickening of the pericardium.
In January 2023, Cardiol Therapeutics Inc. declared that the first patient had been enrolled in the company-sponsored Phase II study evaluating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis.
Geographical Analysis
North America accounted for approximately 40.6% of the market share in 2022
North America is expected to hold the largest market share due to the incidence of pericarditis in patients who received vaccines developed by U.S. companies. Pericarditis causes heart failure that affects more than 64 million people globally, and associated healthcare costs exceed $30 billion annually in the U.S. alone. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.
More than 22 million doses of Moderna have been administered in Canada, where the incidence of myocarditis, pericarditis, or myopericarditis is two to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine than the Pfizer vaccine. Forty-one pericarditis cases were immediately observed after the Moderna vaccine in Canada.
COVID-19 Impact Analysis
Covid 19 had a slight, moderate impact on the pericarditis market. The supply chains were interrupted during the peak period of the infection. Most of the diagnostic centers were shut down due to the implementation of lockdowns worldwide. This impacted the diagnosis and, thus, treatment procedures for cardiovascular diseases, including pericarditis.
Many of them were postponed and diagnosed at later stages as there are many types of pericarditis with different causes; the treatment options vary, with individuals requiring extensive testing that was shut down entirely during the 19 period. Hence, all the research focused on vaccines and covid drug development.
Competitive Landscape
The major global players in the pericarditis market include Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Merck KGaA, Cumberland Pharmaceuticals Inc., Johnson & Johnson Inc., Bayer AG, Midas Pharma GmbH., Alchem International Pvt. Ltd., Takeda Pharmaceutical Company Limited, Azure Pharmaceuticals among others.
Key Developments
• Rabin Medical Center is conducting phase 4 clinical trials to compare the efficacy of NSAID therapy and Dexamethasone therapy in patients suffering from pericarditis. The study start date is February 14, 2020. The estimated completion date is December 2023.
• In March 2021, Kiniksa Pharmaceuticals, Ltd. received the U.S. Food and Drug Administration (FDA) approval for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. It was commercially launched in August 2021.
Why Purchase the Report?
• To visualize the global pericarditis market segmentation based on disease type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pericarditis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global pericarditis market report would provide approximately 63 tables, 65 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing prevalence of virus-associated pericarditis
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side effects of pericardiectomy
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regional Analysis
5.5. Regulatory Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Acute Pericarditis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Incessant Pericarditis
7.4. Chronic Pericarditis
7.5. Others
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Drug*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. Pain Relievers
8.2.2.1.1.1. Aspirin
8.2.2.1.1.2. Ibuprofen
8.2.2.2. Anti-inflammatory drugs
8.2.2.2.1.1. Colchicine
8.2.2.2.1.2. Corticosteroids
8.2.2.2.1.3. Others
8.3. Procedure
8.3.1.1. Pericardiocentesis
8.3.1.2. Pericardiectomy
8.3.1.3. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals and Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiac Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Teva Pharmaceuticals USA, Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Par Pharmaceutical
12.3. Merck KGaA
12.4. Cumberland Pharmaceuticals Inc.
12.5. Johnson & Johnson Inc.
12.6. Bayer AG
12.7. Midas Pharma GmbH.
12.8. Alchem International Pvt. Ltd.
12.9. Takeda Pharmaceutical Company Limited
12.10. Azure Pharmaceuticals
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Teva Pharmaceuticals USA, Inc., 4. Key Developments, Par Pharmaceutical, Merck KGaA, Cumberland Pharmaceuticals Inc., Johnson & Johnson Inc., Bayer AG, Midas Pharma GmbH., Alchem International Pvt. Ltd., Takeda Pharmaceutical Company Limited, Azure Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Pericarditis Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Pericarditis Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Pericarditis Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Pericarditis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Pericarditis Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Pericarditis Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 7 Global Pericarditis Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Pericarditis Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 9 Global Pericarditis Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Pericarditis Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Pericarditis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Pericarditis Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Pericarditis Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 14 North America Pericarditis Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 15 North America Pericarditis Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Pericarditis Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Pericarditis Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 18 South America Pericarditis Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 19 South America Pericarditis Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Pericarditis Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Pericarditis Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 Europe Pericarditis Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 23 Europe Pericarditis Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Pericarditis Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Pericarditis Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Pericarditis Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Pericarditis Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Pericarditis Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Pericarditis Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Pericarditis Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Pericarditis Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Teva Pharmaceuticals USA, Inc.: Overview

Table 33 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 34 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 35 Par Pharmaceutical: Overview

Table 36 Par Pharmaceutical: Product Portfolio

Table 37 Par Pharmaceutical: Key Developments

Table 38 Merck KGaA: Overview

Table 39 Merck KGaA: Product Portfolio

Table 40 Merck KGaA: Key Developments

Table 41 Cumberland Pharmaceuticals Inc.: Overview

Table 42 Cumberland Pharmaceuticals Inc.: Product Portfolio

Table 43 Cumberland Pharmaceuticals Inc.: Key Developments

Table 44 Johnson & Johnson Inc.: Overview

Table 45 Johnson & Johnson Inc.: Product Portfolio

Table 46 Johnson & Johnson Inc.: Key Developments

Table 47 Bayer AG: Overview

Table 48 Bayer AG: Product Portfolio

Table 49 Bayer AG: Key Developments

Table 50 Midas Pharma GmbH.: Overview

Table 51 Midas Pharma GmbH.: Product Portfolio

Table 52 Midas Pharma GmbH.: Key Developments

Table 53 Alchem International Pvt. Ltd.: Overview

Table 54 Alchem International Pvt. Ltd.: Product Portfolio

Table 55 Alchem International Pvt. Ltd.: Key Developments

Table 56 Takeda Pharmaceutical Company Limited: Overview

Table 57 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 58 Takeda Pharmaceutical Company Limited: Key Developments

Table 59 Azure Pharmaceuticals: Overview

Table 60 Azure Pharmaceuticals: Product Portfolio

Table 61 Azure Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 2 Global Pericarditis Market Share, By Disease Type, 2022 & 2031 (%)

Figure 3 Global Pericarditis Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 4 Global Pericarditis Market Share, By End-User, 2022 & 2031 (%)

Figure 5 Global Pericarditis Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Pericarditis Market Y-o-Y Growth, By Disease Type, 2022-2031 (%)

Figure 7 Acute Pericarditis Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 8 Incessant Pericarditis Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 9 Chronic Pericarditis Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 10 Others Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 11 Global Pericarditis Market Y-o-Y Growth, By Treatment Type, 2022-2031 (%)

Figure 12 Drugs Treatment Type in Global Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 13 Procedure Treatment Type in Global Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 14 Global Pericarditis Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 15 Hospitals and Clinics in Global Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 16 Cardiac Centers in Global Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 17 Others in Global Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 18 Global Pericarditis Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 19 North America Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 20 Asia-Pacific Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 21 Europe Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 22 South America Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 23 Middle East and Africa Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 24 North America Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 25 North America Pericarditis Market Share, By Disease Type, 2022 & 2031 (%)

Figure 26 North America Pericarditis Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 27 North America Pericarditis Market Share, By End-User, 2022 & 2031 (%)

Figure 28 North America Pericarditis Market Share, By Country, 2022 & 2031 (%)

Figure 29 South America Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 30 South America Pericarditis Market Share, By Disease Type, 2022 & 2031 (%)

Figure 31 South America Pericarditis Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 32 South America Pericarditis Market Share, By End-User, 2022 & 2031 (%)

Figure 33 South America Pericarditis Market Share, By Country, 2022 & 2031 (%)

Figure 34 Europe Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Pericarditis Market Share, By Disease Type, 2022 & 2031 (%)

Figure 36 Europe Pericarditis Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 37 Europe Pericarditis Market Share, By End-User, 2022 & 2031 (%)

Figure 38 Europe Pericarditis Market Share, By Country, 2022 & 2031 (%)

Figure 39 Asia-Pacific Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 40 Asia-Pacific Pericarditis Market Share, By Disease Type, 2022 & 2031 (%)

Figure 41 Asia-Pacific Pericarditis Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 42 Asia-Pacific Pericarditis Market Share, By End-User, 2022 & 2031 (%)

Figure 43 Asia-Pacific Pericarditis Market Share, By Country, 2022 & 2031 (%)

Figure 44 Middle East & Africa Pericarditis Market Value, 2022-2031 (US$ Million)

Figure 45 Middle East & Africa Pericarditis Market Share, By Disease Type, 2022 & 2031 (%)

Figure 46 Middle East & Africa Pericarditis Market Share, By Treatment Type, 2022 & 2031 (%)

Figure 47 Middle East & Africa Pericarditis Market Share, By End-User, 2022 & 2031 (%)

Figure 48 Teva Pharmaceuticals USA, Inc.: Financials

Figure 49 Par Pharmaceutical: Financials

Figure 50 Merck KGaA: Financials

Figure 51 Cumberland Pharmaceuticals Inc.: Financials

Figure 52 Johnson & Johnson Inc.: Financials

Figure 53 Bayer AG: Financials

Figure 54 Midas Pharma GmbH.: Financials

Figure 55 Alchem International Pvt. Ltd.: Financials

Figure 56 Takeda Pharmaceutical Company Limited: Financials

Figure 57 Azure Pharmaceuticals : Financials

세계 심낭염 시장 – 2023-2030

Global Pericarditis Market - 2023-2030